ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

ClinicalTrials.gov ID: NCT04285515

Public ClinicalTrials.gov record NCT04285515. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder

Study identification

NCT ID
NCT04285515
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Enrollment
488 participants

Conditions and interventions

Interventions

  • Lumateperone Drug
  • Placebos Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 26, 2020
Primary completion
Nov 29, 2022
Completion
Nov 29, 2022
Last update posted
Mar 18, 2025

2020 – 2022

United States locations

U.S. sites
13
U.S. states
7
U.S. cities
13
Facility City State ZIP Site status
Clinical Site Garden Grove California 92845
Clinical Site Oceanside California 92056
Clinical Site Sherman Oaks California 91403
Clinical Site Lauderhill Florida 33319
Clinical Site Miami Florida 33122
Clinical Site Orange City Florida 32763
Clinical Site Atlanta Georgia 30331
Clinical Site Decatur Georgia 30030
Clinical Site O'Fallon Missouri 63368
Clinical Site Cedarhurst New York 11694
Clinical Site New York New York 10128
Clinical Site Charlotte North Carolina 28211
Clinical Site Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04285515, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 18, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04285515 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →